{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:24:45Z","timestamp":1790623485171,"version":"4.1.0"},"reference-count":122,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T00:00:00Z","timestamp":1528761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Treatment with anti-TNF-\u03b1 (tumor necrosis factor), one of the pivotal cytokines, was introduced to clinical practice at the end of last century and revolutionized the treatment of rheumatoid arthritis (RA) as well as many other inflammatory conditions. Such a treatment may however bring many safety issues regarding infections, tuberculosis, as well as cardiovascular diseases, including heart failure. Given the central role of proinflammatory cytokines in RA, atherosclerosis, and congestive heart failure (CHF), such a treatment might result in better control of the RA process on the one side and improvement of heart function on the other. Unfortunately, at the beginning of this century two randomized controlled trials failed to show any benefit of anti-TNF treatment in patients with heart failure (HF), suggesting direct negative impact of the treatment on morbidity and mortality in HF patients. As a result the anti-TNF treatment is contraindicated in all patients with heart failure and a substantial portion of patients with RA and impaired heart function are not able to benefit from the treatment. The role of TNF in CHF and RA differs substantially with regard to the source and pathophysiological function of the cytokine in both conditions, therefore negative data from CHF studies should be interpreted with caution. At least some of RA patients with heart failure may benefit from anti-TNF treatment, as it results not only in the reduction of inflammation but also contributes significantly to the improvement of cardiac function. The paper addresses the epidemiological data of safety of anti-TNF treatment in RA patients with the special emphasis to basic pathophysiological mechanisms via which TNF may act differently in both diseases.<\/jats:p>","DOI":"10.3390\/ijms19061739","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T10:58:32Z","timestamp":1528801112000},"page":"1739","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Bimodal Function of Anti-TNF Treatment: Shall We Be Concerned about Anti-TNF Treatment in Patients with Rheumatoid Arthritis and Heart Failure?"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8376-6527","authenticated-orcid":false,"given":"Przemyslaw J.","family":"Kotyla","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Rheumatology and Clinical Immunology, Medical Faculty in Katowice, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.semarthrit.2006.08.006","article-title":"Incidence and prevalence of rheumatoid arthritis, based on the 1987 american college of rheumatology criteria: A systematic review","volume":"36","author":"Alamanos","year":"2006","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Taverner, D., Vallve, J.C., Ferre, R., Paredes, S., Masana, L., and Castro, A. (2018). Variables associated with subclinical atherosclerosis in a cohort of rheumatoid arthritis patients: Sex-specific associations and differential effects of disease activity and age. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193690"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.atherosclerosis.2018.02.036","article-title":"The gut microbiome and elevated cardiovascular risk in obesity and autoimmunity","volume":"271","author":"Kasselman","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.biopha.2017.05.055","article-title":"Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy","volume":"92","author":"Alam","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-065X.2008.00626.x","article-title":"Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics","volume":"223","author":"Feldmann","year":"2008","journal-title":"Immunol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41590-018-0102-6","article-title":"Atherogenic dyslipidemia promotes autoimmune follicular helper T cell responses via IL-27","volume":"19","author":"Ryu","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/art.23650","article-title":"High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: A population-based cohort study","volume":"58","author":"Kremers","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Naranjo, A., Sokka, T., Descalzo, M.A., Calvo-Al\u00e9n, J., H\u00f8rslev-Petersen, K., Luukkainen, R.K., Combe, B., Burmester, G.R., Devlin, J., and Ferraccioli, G. (2008). Cardiovascular disease in patients with rheumatoid arthritis: Results from the QUEST-RA study. Arthritis Res. Ther., 10.","DOI":"10.1186\/ar2383"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.23811","article-title":"The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis","volume":"58","author":"Wolfe","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Bengtsson, K., Jacobsson, L.T., Rydberg, B., Kvist, G., Torstenson, T., Dehlin, M., Hilme, E., Lindhe, A., Wallerstedt, S.M., and Forsblad-d'Elia, H. (2016). Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: A register-based study. BMC Musculoskelet. Disord., 17.","DOI":"10.1186\/s12891-016-1354-7"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/keu224","article-title":"Cardiovascular risk in rheumatoid arthritis: Recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment","volume":"53","author":"Choy","year":"2014","journal-title":"Rheumatology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/rheumatology\/kep252","article-title":"Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: A systematic review and meta-analysis of cohort studies","volume":"48","author":"Meune","year":"2009","journal-title":"Rheumatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.acvd.2010.03.007","article-title":"High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis","volume":"103","author":"Meune","year":"2010","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.24092","article-title":"Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies","volume":"59","author":"Choi","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Widdifield, J., Paterson, J.M., Huang, A., and Bernatsky, S. (2018). Causes of death in rheumatoid arthritis: How do they compare to the general population?. Arthritis Care Res.","DOI":"10.1002\/acr.23548"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Logstrup, B.B., Ellingsen, T., Pedersen, A.B., Kjaersgaard, A., Botker, H.E., and Maeng, M. (2018). Development of heart failure in patients with rheumatoid arthritis: A danish population-based study. Eur. J. Clin. Investig.","DOI":"10.1111\/eci.12915"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.amjmed.2008.06.014","article-title":"Role of inflammation in atherosclerosis associated with rheumatoid arthritis","volume":"121","author":"Libby","year":"2008","journal-title":"Am. J. Med."},{"key":"ref_21","first-page":"435","article-title":"Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis","volume":"32","author":"Dessein","year":"2005","journal-title":"J. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1253\/circj.CJ-09-0274","article-title":"Rheumatoid arthritis: Model of systemic inflammation driving atherosclerosis","volume":"73","author":"Ku","year":"2009","journal-title":"Circ. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar3442","article-title":"Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: A five year prospective study","volume":"13","author":"Innala","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/art.20853","article-title":"Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study","volume":"52","author":"Crowson","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.20855","article-title":"The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years","volume":"52","author":"Nicola","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/art.23798","article-title":"The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population","volume":"58","author":"Davis","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ahj.2013.07.010","article-title":"Rheumatoid arthritis and cardiovascular disease","volume":"166","author":"Crowson","year":"2013","journal-title":"Am. Heart J."},{"key":"ref_28","first-page":"2167","article-title":"Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"33","author":"Han","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1196\/annals.1422.038","article-title":"Precocious atherosclerosis in rheumatoid arthritis: Role of traditional and disease-related cardiovascular risk factors","volume":"1108","author":"Gerli","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Luchetti, M.M., Benfaremo, D., and Gabrielli, A. (2017). Biologics in inflammatory and immunomediated arthritis. Curr. Pharm. Biotechnol.","DOI":"10.2174\/1389201019666171226151852"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/acr.23303","article-title":"Treatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic agent in a global comparative observational study","volume":"69","author":"Choy","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_32","first-page":"192","article-title":"Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: A real-world study","volume":"35","author":"Lampropoulos","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/1744666X.2017.1295850","article-title":"The role and therapeutic targeting of IL-6 in rheumatoid arthritis","volume":"13","author":"Narazaki","year":"2017","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 Update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","first-page":"211","article-title":"Who might be predisposed to the development of serious side effects when treated with TNF-\u03b1 antagonist?","volume":"24","author":"Kotyla","year":"2006","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s10067-007-0657-3","article-title":"Treatment with infliximab may contribute to the development of peripheral neuropathy among the patients with rheumatoid arthritis","volume":"26","author":"Kotyla","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ddr.21285","article-title":"Safety of anti-TNF therapies in immune-mediated inflammatory diseases: Focus on infections and malignancy","volume":"76","author":"Pereira","year":"2015","journal-title":"Drug Dev. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/14712598.2017.1346078","article-title":"Safety profile of biological therapies for treating rheumatoid arthritis","volume":"17","author":"Canete","year":"2017","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-017-1496-5","article-title":"One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: Data from a national U.S. Rheumatoid arthritis registry","volume":"20","author":"Harrold","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Rutherford, A.I., Patarata, E., Subesinghe, S., Hyrich, K.L., and Galloway, J.B. (2018). Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: Results from the British society for rheumatology biologics register for rheumatoid arthritis. Rheumatology.","DOI":"10.1136\/annrheumdis-2017-212825"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.trsl.2015.05.006","article-title":"Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis","volume":"167","author":"Shen","year":"2016","journal-title":"Transl. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","article-title":"Pathogenetic insights from the treatment of rheumatoid arthritis","volume":"389","author":"McInnes","year":"2017","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14728214.2017.1269743","article-title":"Inflammation and beyond: New directions and emerging drugs for treating atherosclerosis","volume":"22","author":"Bertrand","year":"2017","journal-title":"Expert. Opin. Emerg. Drugs"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.2174\/0929867322666150415145814","article-title":"The role and predictive value of cytokines in atherosclerosis and coronary artery disease","volume":"22","author":"Tousoulis","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc2628","article-title":"Tumour necrosis factor and cancer","volume":"9","author":"Balkwill","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CEJ.0b013e3282b6fcff","article-title":"Antitumor necrosis factor-\u03b1 therapy and potential cancer inhibition","volume":"17","author":"Williams","year":"2008","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_47","first-page":"1","article-title":"The diverse roles of the TNF axis in cancer progression and metastasis","volume":"11","author":"Ham","year":"2016","journal-title":"Trends Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cyto.2016.08.035","article-title":"Intracellular regulation of TNF activity in health and disease","volume":"101","author":"Varfolomeev","year":"2018","journal-title":"Cytokine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2016.08.003","article-title":"TNF activity and T cells","volume":"101","author":"Mehta","year":"2018","journal-title":"Cytokine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000289196","article-title":"Transcriptional control of the TNF gene","volume":"11","author":"Falvo","year":"2010","journal-title":"Curr. Dir. Autoimmun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/CS20080196","article-title":"Role of TNF-\u03b1 in vascular dysfunction","volume":"116","author":"Zhang","year":"2009","journal-title":"Clin. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":"A metalloproteinase disintegrin that releases tumour-necrosis factor-\u03b1 from cells","volume":"385","author":"Black","year":"1997","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"9292","DOI":"10.1073\/pnas.88.20.9292","article-title":"The two different receptors for tumor necrosis factor mediate distinct cellular responses","volume":"88","author":"Tartaglia","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants\u2014past, present and future","volume":"25","author":"Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.2741\/4265","article-title":"TNF\/TNFr: Drug target for autoimmune diseases and immune-mediated inflammatory diseases","volume":"19","author":"Doss","year":"2014","journal-title":"Front. Biosci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3389\/fimmu.2013.00478","article-title":"TNF receptor 2 and disease: Autoimmunity and regenerative medicine","volume":"4","author":"Faustman","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.bbamcr.2013.06.001","article-title":"Crosstalk between apoptosis, necrosis and autophagy","volume":"1833","author":"Nikoletopoulou","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cytogfr.2014.03.004","article-title":"Regulation and dysregulation of tumor necrosis factor receptor-1","volume":"25","author":"Puimege","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_60","first-page":"27","article-title":"Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells","volume":"146","author":"Bradley","year":"1995","journal-title":"Am. J. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.4049\/jimmunol.151.9.4637","article-title":"Stimulation of human T-cell proliferation by specific activation of the 75-kda tumor necrosis factor receptor","volume":"151","author":"Tartaglia","year":"1993","journal-title":"J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.2174\/0929867043364694","article-title":"Function and regulation of tumor necrosis factor receptor type 2","volume":"11","author":"Carpentier","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"H1189","DOI":"10.1152\/ajpheart.00904.2015","article-title":"TNF receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and promotes a neuroadrenergic-like fate","volume":"311","author":"Hamid","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.03.009","article-title":"TRAF2 multitasking in TNF receptor-induced signaling to Nf-\u03baB, map kinases and cell death","volume":"116","author":"Borghi","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2567.2011.03460.x","article-title":"The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4+ FoxP3+ regulatory T cells","volume":"133","author":"Chen","year":"2011","journal-title":"Immunology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000338166","article-title":"Inflammatory cytokines in heart failure: Mediators and markers","volume":"122","author":"Gullestad","year":"2012","journal-title":"Cardiology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cca.2014.09.001","article-title":"Inflammatory cytokines as biomarkers in heart failure","volume":"443","author":"Ueland","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_69","first-page":"R577","article-title":"Tumor necrosis factor in the heart","volume":"274","author":"Meldrum","year":"1998","journal-title":"Am. J. Physiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2143\/AC.58.2.2005264","article-title":"Role of nitric oxide and oxidative stress in ischaemic myocardial injury and preconditioning","volume":"58","author":"Berges","year":"2003","journal-title":"Acta Cardiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1161\/01.RES.0000014451.75415.36","article-title":"Myocardial dysfunction with coronary microembolization: Signal transduction through a sequence of nitric oxide, tumor necrosis factor-\u03b1, and sphingosine","volume":"90","author":"Thielmann","year":"2002","journal-title":"Circ. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/01.RES.0000150734.79804.92","article-title":"Cytokine-induced modulation of cardiac function","volume":"95","author":"Prabhu","year":"2004","journal-title":"Circ. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/01.RES.0000043825.01705.1B","article-title":"Inflammatory mediators and the failing heart: Past, present, and the foreseeable future","volume":"91","author":"Mann","year":"2002","journal-title":"Circ. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00395-010-0146-8","article-title":"Central TNF inhibition results in attenuated neurohumoral excitation in heart failure: A role for superoxide and nitric oxide","volume":"106","author":"Guggilam","year":"2011","journal-title":"Basic Res. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1161\/CIRCULATIONAHA.112.150656","article-title":"Cardiokines: Recent progress in elucidating the cardiac secretome","volume":"126","author":"Shimano","year":"2012","journal-title":"Circulation"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10741-010-9180-8","article-title":"TNF\u03b1 in myocardial ischemia\/reperfusion, remodeling and heart failure","volume":"16","author":"Kleinbongard","year":"2011","journal-title":"Heart Fail. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cellsig.2006.06.007","article-title":"\u03b22 Adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-\u03baB-independent mechanisms","volume":"19","author":"Tan","year":"2007","journal-title":"Cell Signal."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.cardiores.2004.08.013","article-title":"Cardiac oxidative stress in acute and chronic isoproterenol-infused rats","volume":"65","author":"Zhang","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2004.04.185","article-title":"\u03b2-Adrenergic stimulation induces interleukin-18 expression via \u03b22-AR, PI3K, Akt, IKK, and NF-\u03baB","volume":"319","author":"Chandrasekar","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1161\/01.CIR.101.20.2338","article-title":"Chronic \u03b2-adrenergic stimulation induces myocardial proinflammatory cytokine expression","volume":"101","author":"Murray","year":"2000","journal-title":"Circulation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00395-011-0196-6","article-title":"Tumor necrosis factor receptor 2 signaling limits \u03b2-adrenergic receptor-mediated cardiac hypertrophy in vivo","volume":"106","author":"Garlie","year":"2011","journal-title":"Basic Res. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.yjmcc.2003.09.019","article-title":"Tumor necrosis factor-induced protection of the murine heart is independent of p38-MAPK activation","volume":"35","author":"Tanno","year":"2003","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/08820139.2014.921689","article-title":"Dual effects of tumor necrosis factor \u03b1 on myocardial injury following prolonged hypoperfusion of the heart","volume":"44","author":"Asgeri","year":"2015","journal-title":"Immunol. Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: Results of the randomized etanercept worldwide evaluation (renewal)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-\u03b1, in patients with moderate-to-severe heart failure: Results of the anti-TNF therapy against congestive heart failure (attach) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/eurheartj\/ehm037","article-title":"How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography associations of the european society of cardiology","volume":"28","author":"Paulus","year":"2007","journal-title":"Eur. Heart J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1152\/japplphysiol.00374.2015","article-title":"Myocardial hypertrophy and its role in heart failure with preserved ejection fraction","volume":"119","author":"Heinzel","year":"2015","journal-title":"J. Appl. Physiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection FractionClinical Perspective","volume":"124","author":"Zile","year":"2011","journal-title":"Circulation"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jacc.2016.12.033","article-title":"Association between rheumatoid arthritis and risk of ischemic and nonischemic heart failure","volume":"69","author":"Mantel","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/0735-1097(95)00589-7","article-title":"Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)","volume":"27","author":"Kapadia","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00296-007-0473-8","article-title":"Diastolic heart function in RA patients","volume":"28","author":"Wislowska","year":"2008","journal-title":"Rheumatol. Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1540-8175.2007.00422.x","article-title":"Tissue Doppler imaging in the evaluation of the left and right ventricular diastolic functions in rheumatoid arthritis","volume":"24","author":"Birdane","year":"2007","journal-title":"Echocardiography"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10741-017-9639-y","article-title":"Effects of exercise training on anabolic and catabolic markers in patients with chronic heart failure: A systematic review","volume":"22","author":"Lee","year":"2017","journal-title":"Heart Fail. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ejheart.2008.02.008","article-title":"Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure","volume":"10","author":"Miettinen","year":"2008","journal-title":"Eur. J. Heart Fail."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13075-017-1401-2","article-title":"High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: A post hoc analysis of the RISING study","volume":"19","author":"Takeuchi","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_98","first-page":"14","article-title":"Etanercept increases tumor necrosis factor-\u03b1 level but not sFas level in patients with rheumatoid arthritis","volume":"17","author":"Kotyla","year":"2015","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1053-2498(00)00173-X","article-title":"Expression of proinflammatory cytokines in the failing human heart: Comparison of recent-onset and end-stage congestive heart failure","volume":"19","author":"Kubota","year":"2000","journal-title":"J. Heart Lung Transplant."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.humimm.2015.10.008","article-title":"The relationship between body weight and inflammation: Lesson from anti-TNF-\u03b1 antibody therapy","volume":"77","author":"Peluso","year":"2016","journal-title":"Hum. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s10067-016-3249-2","article-title":"Relative expression and correlation of tumor necrosis factor-\u03b1, interferon-\u03b3, and interleukin-17 in the rheumatoid synovium","volume":"35","author":"Nakajima","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1111\/j.1600-6143.2009.02831.x","article-title":"TNF receptors differentially signal and are differentially expressed and regulated in the human heart","volume":"9","author":"Brookes","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1161\/CIRCULATIONAHA.108.802918","article-title":"Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: Role of nuclear factor-\u03baB and inflammatory activation","volume":"119","author":"Hamid","year":"2009","journal-title":"Circulation"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1161\/01.CIR.0000124227.00670.AB","article-title":"Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-\u03b1-induced cardiomyopathy","volume":"109","author":"Higuchi","year":"2004","journal-title":"Circulation"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/apha.12489","article-title":"Tumour necrosis factor-\u03b1 contributes to improved cardiac ischaemic tolerance in rats adapted to chronic continuous hypoxia","volume":"214","author":"Chytilova","year":"2015","journal-title":"Acta Physiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/stem.1433","article-title":"TNF, acting through inducibly expressed TNFR2, drives activation and cell cycle entry of c-kit+ cardiac stem cells in ischemic heart disease","volume":"31","author":"Lu","year":"2013","journal-title":"Stem Cells"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e5868","DOI":"10.1590\/1414-431x20175868","article-title":"Etanercept protects rat cardiomyocytes against hypertrophy by regulating inflammatory cytokines secretion and cell apoptosis","volume":"50","author":"Li","year":"2017","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"I350","DOI":"10.1161\/hc37t1.094851","article-title":"Inhibition of tumor necrosis factor-\u03b1 improves postischemic recovery of hypertrophied hearts","volume":"104","author":"Stamm","year":"2001","journal-title":"Circulation"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Putko, B.N., Wang, Z., Lo, J., Anderson, T., Becher, H., Dyck, J.R., Kassiri, Z., and Oudit, G.Y. (2014). Circulating levels of tumor necrosis factor-\u03b1 receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: Evidence for a divergence in pathophysiology. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099495"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.4049\/jimmunol.155.10.5038","article-title":"Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration","volume":"155","author":"Suffredini","year":"1995","journal-title":"J. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","article-title":"Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis","volume":"124","author":"Utz","year":"2003","journal-title":"Chest"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1752-8062.2008.00013.x","article-title":"Effect of the soluble TNF-antagonist etanercept on tumor necrosis factor bioactivity and stability","volume":"1","author":"Mann","year":"2008","journal-title":"Clin. Transl. Sci."},{"key":"ref_113","first-page":"469","article-title":"Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: Correlation of TNF-\u03b1 serum level with clinical response and benefit from changing dose or frequency of infliximab infusions","volume":"23","author":"Edrees","year":"2005","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.4049\/jimmunol.164.12.6193","article-title":"Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages","volume":"164","author":"Eissner","year":"2000","journal-title":"J. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/eci.13.14","article-title":"Importance of reverse signaling of the TNF superfamily in immune regulation","volume":"9","author":"Juhasz","year":"2013","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.trsl.2010.09.005","article-title":"Tumor necrosis factor-\u03b1 blockade, cardiovascular outcomes, and survival in rheumatoid arthritis","volume":"157","author":"Pan","year":"2011","journal-title":"Transl. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","article-title":"Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"116","author":"Wolfe","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","article-title":"Does tumor necrosis factor \u03b1 inhibition promote or prevent heart failure in patients with rheumatoid arthritis?","volume":"58","author":"Listing","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/annrheumdis-2016-210997","article-title":"Low disease activity (DAS28\u22643.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: A time-dependent Cox regression analysis in a large cohort study","volume":"76","author":"Arts","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/art.23280","article-title":"Tumor necrosis factor inhibition: A part of the solution or a part of the problem of heart failure in rheumatoid arthritis?","volume":"58","author":"Gabriel","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3899\/jrheum.110751","article-title":"Infliximab treatment increases left ventricular ejection fraction in patients with rheumatoid arthritis: Assessment of heart function by echocardiography, endothelin 1, interleukin 6, and NT-pro brain natriuretic peptide","volume":"39","author":"Kotyla","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4081\/monaldi.2015.716","article-title":"Left ventricular function in rheumatoid arthritis during anti-TNF-\u03b1 treatment: A speckle tracking prospective echocardiographic study","volume":"84","author":"Vizzardi","year":"2016","journal-title":"Monaldi Arch. Chest Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/6\/1739\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:08:17Z","timestamp":1760195297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/6\/1739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,12]]},"references-count":122,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"alternative-id":["ijms19061739"],"URL":"https:\/\/doi.org\/10.3390\/ijms19061739","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,12]]}}}